Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $4

Benzinga Newsdesk www.benzinga.com Negative 95.7%

Neg 95.7% Neu 0% Pos 0%

Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and lowers the price target from $5 to $4.